Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company’s iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.
Company Background and Technology
Founded in 2022, Celregen Therapeutics boasts iPSC rapid reprogramming technology, an iPSC gene editing platform, and a bioinformatics-guided differentiation technology platform for different germ layers. These platforms cover all upstream and downstream research and development processes of iPSC and its derivative products, positioning Celregen at the forefront of regenerative medicine innovation.
Funding Utilization
The funds from this financing round will be strategically allocated to several key areas. A significant portion will be dedicated to constructing the iPSC regenerative medicine platform, which will serve as the foundation for developing innovative therapies. Additionally, resources will be directed toward initiating clinical studies for CRG-002 and CRG-101, with the goal of advancing these promising candidates through the development pipeline and ultimately bringing them to market.-Fineline Info & Tech
Leave a Reply